BioVex Bags $40M for Late-Stage Trial with Oncolytic Virus Technology

Data from trial with OncoVEX GM-CSF in metastatic melanoma is expected in 2010. BioVex raised $40 million in the first close of a series F...

La Jolla Institute to Test IVT’s Delivery Platform with Infectious Disease...

Preclinical flu and arenavirus vaccines will be coupled with DepoVax technology. ImmunoVaccine Technologies (IVT) signed an agreement with the La Jolla Institute for Allergy &...

IMPROVING THE EFFECTIVENESS OF THE TB VACCINE

- Interview with Robert Hunter Jr., M.D., Ph.D., Chair of the Department of Pathology and Laboratory Medicine at the University of Texas Medical School in Houston

Morphotek to Develop Antibodies to Validate Antigens Found by HGS

Companies reserve the right to participate in commercialization of each candidate in oncology and immunology. Morphotek agreed to discover, develop, and commercialize mAbs targeting antigens discovered...

Teva-Compugen Alliance Yields Biomarkers for Detection of Drug-Induced Kidney Toxicity

Teva will use the panel in its R&D activities, and Compugen plans to commercialize it later this year. Teva Pharmaceutical Industries exercised its option to...

Xcellerex, Dowpharma, Biopharm, and deltaDot Win $11M Technology Development Contract

Goal is to increase the productivity and quality of vaccine and mAb production. Xcellerex, Dowpharma, Biopharm Services, and deltaDot have been awarded $11 million to...

Novartis Licenses MDRNA’s siRNA Delivery Technology for $7.25M

Separate agreement allows companies to negotiate an R&D collaboration. Novartis Pharmaceuticals entered a licensing agreement with MDRNA to pay $7.25 million in up-front fees for...

PATH Malaria Vaccine Initiative Allies with VGX

Company’s development platform and delivery system will be tested. The PATH Malaria Vaccine Initiative (MVI) agreed to evaluate VGX Pharmaceuticals’ (VGX) SynCon™ DNA vaccine development...

Legislation on Biosimilars

With all political eyes on making healthcare more affordable, the issue of how to bring biosimilars to market has everyone riled up. The need for cheaper drug options is pitted against the importance of protecting innovation.

Brand-name firms ask for significant clinical trial data before approval to ensure the new versions are true copies with the closest possible safety profile and efficacy. They’d also like at least 14 years of market exclusivity to ensure the ability to generate profits after a long and costly development process. Companies focusing on biosimilars would prefer to avoid going through every clinical trial phase, stating that proving safety and efficacy can be done in a quicker manner. And of course, they want to get their biosimilars on the market asap. Politicians are currently reviewing a proposal that would confer at least five years of market exclusivity. So where do you stand?

IBA Pads Assay Development Services with Acquisition of Axela Technology

Firm gains access to dotLab and will increase the number of biomarker assays that work with it. The Institute of Bioanalytics (IBA) has purchased Axela’s...
Scroll Up